Zydus Lifesciences Limited (ZYDUSLIFE)
Investor Presentation
Investor Presentation - Q2 FY27
- Total revenues grew 29% YoY to Rs. 79,096 mn; EBITDA Rs. 18,945 mn (24.0% margin)
- India formulations grew 19% YoY, outperforming market; chronic portfolio share at 56.9%
- North America formulations grew 20.8% YoY; 5 new product launches in quarter
- International markets up 33.2% YoY with broad-based growth in emerging and European markets
- Consumer wellness grew 29% YoY in India; international business up 12% like-to-like
- Capex Rs. 4,655 mn in Q2 FY27; Net debt Rs. 51,998 mn as of Sep 30, 2026
- R&D spend 8.3% of revenues; USFDA approvals and new product filings ongoing
- ESG rating improved to 71/100, ranked top 2 in Indian pharma sector
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 ZYDUSLIFE — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add ZYDUSLIFE to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Zydus Lifesciences Limited
Important.
The summary above is generated automatically from Zydus Lifesciences Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.